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A B S T R A C T
Purpose
The After Mapping of the Axilla: Radiotherapy or Surgery? (AMAROS) phase III study compares
axillary lymph node dissection (ALND) and axillary radiation therapy (ART) in early breast cancer
patients with tumor-positive sentinel nodes. In the ART arm, the extent of nodal involvement
remains unknown, which could have implications on the administration of adjuvant therapy. In this
preliminary analysis, we studied the influence of random assignment to ALND or ART on the
choice for adjuvant treatment.
Patients and Methods
In the first 2,000 patients enrolled in the AMAROS trial, we analyzed the administration of adjuvant
systemic therapy. Multivariate analysis was used to assess variables affecting the administration
of adjuvant chemotherapy. Adjuvant therapy was applied according to institutional guidelines.
Results
Of 2,000 patients, 566 patients had a positive sentinel node and were treated per random
assignment. There was no significant difference in the administration of adjuvant systemic
therapy. In the ALND and ART arms, 58% (175 of 300) and 61% (162 of 266) of the patients,
respectively, received chemotherapy. Endocrine therapy was administered in 78% (235 of 300) of
the patients in the ALND arm and in 76% (203 of 266) of the patients in the ART arm. Treatment
arm was not a significant factor in the decision, and no interactions between treatment arm and
other factors were observed. Multivariate analysis showed that age, tumor grade, multifocality,
and size of the sentinel node metastasis significantly affected the administration of chemotherapy.
Within the ALND arm, the extent of nodal involvement remained not significant in a sensitivity
multivariate analysis.
Conclusion
Absence of knowledge regarding the extent of nodal involvement in the ART arm appears to have
no major impact on the administration of adjuvant therapy.
J Clin Oncol 28:731-737. © 2009 by American Society of Clinical Oncology
INTRODUCTION
The primary site of lymphatic drainage of the
breast is the axillary region. Hence, the axillary
lymph nodes are often the first site of regional
metastatic disease in breast cancer. Axillary clear-
ance provides knowledge on the presence or
absence of dissemination to the axillary lymph
nodes—important information for prognosis and
staging.1 It also ensures regional tumor control
and may in some cases improve survival.2 There-
fore, axillary lymph node dissection (ALND) of
the axilla was standard of care in patients with
breast cancer for many years.
With the widespread introduction of the senti-
nel node biopsy procedure, the question was raised
about how to deal with potential additional lymph
node metastases in case of a positive sentinel node.
AfterALND,morbidity including lymphedemaand
decreased arm and shoulder function is seen in 5%
to 39% of the patients.3-5 A less invasive alternative
for ALND in the case of positive sentinel nodes
might be axillary radiation therapy (ART).
In the 1960s and 1970s, the value of ART was
analyzed in a series of randomized clinical trials.6-11
The original objective was to test the hypothesis of
improving survival bymaintaining an immunologic
barrier in the axillary lymph nodes. With respect to
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the endpoint of survival, nodifferencewas foundbetweenALNDand
ART except in a British trial that showed worse survival due to lower
axillary control rates afterART.9Conversely, the only trial focusingon
patients with clinically negative lymph nodes showed a low axillary
recurrence rate of 4% in the ART arm after 25 years.12
To investigate differences in regional control, survival, and
long-term morbidity between ALND and ART, an international
multicenter phase III trial was initiated in 2001 by the European
Organisation for Research and Treatment of Cancer (EORTC). This
study is called the After Mapping of the Axilla: Radiotherapy or Sur-
gery? (AMAROS) trial (EORTC 10981-22023 trial) and is ongoing.
Patients with clinically negative lymph nodes are randomly assigned
between ALND and ART in case of a tumor-positive sentinel node
biopsy. Themain objective of the trial is to show noninferiority of the
radiotherapy arm (ART) compared with the ALND treatment arm
with respect to axillary recurrence-free rate in sentinel node–positive
patients. In total, 4,766 patients have to be included. Up toDecember
2008, more than 4,000 patients have been enrolled.
Besides survival and locoregional control, another concern is the
extent of nodal involvement,which remains unknownwhenALND is
replacedbyART.Moreextensivenodal involvement is associatedwith
a higher TNM classification and poorer prognosis.13 Hence, these
patients are likely to have a larger absolute benefit from adjuvant
systemic and radiation therapy. Therefore, nodal status is commonly
used to select patients for adjuvant treatment. The aim of this prelim-
inary analysis was to analyze the influence of ART, and consequently
an unknown extent of nodal involvement, on decisions concerning
adjuvant systemic treatment.
PATIENTS AND METHODS
After obtaining permission from the EORTC Independent Data Monitoring
Committee, the first 2,000 patients with operable unifocal invasive breast
cancer (5 to 30mm) and clinically negative lymph nodes who had enrolled in
the AMAROS trial were analyzed. The CONSORT diagram and study design
of the AMAROS trial are shown in Figures 1 and 2, respectively. Quality
assurance for the sentinel node procedure and axillary radiotherapy was de-
scribed previously.14,15 Exclusion criteria were metastatic disease, previous
treatment of the axilla by surgery or radiotherapy, previous treatment of
cancer (except basal cell carcinoma of the skin and in situ carcinoma of the
cervix), or pregnancy. Between 2001 and 2005, 2,000 patients were entered
onto the AMAROS trial from 26 institutions in Europe. Before the sentinel
node biopsy (SNB) procedure, patients were randomly assigned between
ALND and ART. This allowed the application of breast surgery and axillary
surgery simultaneously when positive sentinel nodes were found by analyzing
frozen sections. Random assignment was accomplished centrally by the
EORTC headquarters, and patients were stratified according to institution.
The AMAROS trial was approved by the institutional ethical committees, and
informed consent was obtained for all patients.
Surgery
In 1,744 patients, SNB was performed using the combined method of
blue dye and isotope with intraoperative detection using a gamma probe. A
Assessed for Eligibility
(N = 2,000) 
Eligible patients
(n = 1,959) 
Did not meet inclusion criteria
(n = 41)
Eligible patients + SNB done
(n = 1,888)
SNB not identified (n = 65)
SNB not done (n = 6)
SNB negative 
(n = 1,220) 
SNB positive nonaxillary 
(n = 10) 
SNB positive 
(n = 658) 
Allocated to ALND  
(n = 350) 
Allocated to ART 
(n = 308) 
Received ALND 
(n = 300) 
Received ART  
(n = 266) 
Off-protocol treatment (n = 50)
Crossover (n = 16)
No further treatment (n = 7)
Other violations (n = 27)
Off-protocol treatment (n = 42)
Crossover (n = 25)
No further treatment (n = 8)
Other violations (n = 9)
Fig 1. CONSORT flow chart. The final
566 patients with positive sentinel nodes
and treated according their random as-
signment (axillary lymph node dissection
[ALND] v axillary radiation therapy [ART])
form the basis of this study. SNB, sentinel
node biopsy.
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minority of SNBswere performedwith isotope (n181) or bluedye (n19)
only. Lymphoscintigrams were recommended although not mandatory. Ra-
dioactive and blue-stained nodeswere removed togetherwith nodes thatwere
highly suggestive of metastatic cancer on palpation. Subsequently, mastec-
tomy or breast-conserving surgery was carried out. Patients with tumor-
positive sentinel nodes who were allocated to the ALND arm underwent level
I and II ALNDs within 12 weeks. Removal of at least eight lymph nodes
was mandatory.
Radiotherapy
Sentinel node–positivepatients allocated to theARTarmwere irradiated
within 12 weeks after surgery. All three levels of the axilla together with the
medial part of the supraclavicular fossawere considered clinical target volume.
The prescribed dose to the axilla was 50 Gy in 25 fractions of 2 Gy, 5 days a
week. Postoperative axillary irradiation in patients undergoing ALND was
allowed inpatientswith fourormore tumor-positivenodes (pN2orpN3) and
applied according to the institutional protocols.
Pathology
As aminimal requirement, three histologic levels (500-micron distance)
for each sentinelnodewere examined.Oneach level, twoparallel sectionswere
performed: one for immunohistochemistry and one for hematoxylin and
eosin staining. immunohistochemistry staining was performed for markers
containing at least cytokeratin 8 and18 (eg,CAM5.2). Immunohistochemical
stainingwas required onlywhenhematoxylin and eosin stainingwas negative.
Tumor deposits were categorized as isolated tumor cells ( 0.2 mm), micro-
metastases (0.2 to 2mm), or macrometastases ( 2mm).
Adjuvant Systemic Therapy
The indications to offer systemic therapy were not fixed in the protocol.
The actual chemotherapies and endocrine therapies were given according to
the local guidelines. To obtain an objective criterion for the administration of
adjuvant chemotherapy, we used the clinicopathologic risk as predicted by
Adjuvant! and a predefined cutoff value of clinical high- and low-risk patients,
as previously described byMook et al.16
The Adjuvant! software version 8.0 (www.adjuvantonline.com) calcu-
lated 10-year survival probability based onpatient’s age, comorbidities, tumor
size, tumor grade, estrogen receptor (ER) status, and number of positive
axillary lymph nodes.17,18 Since the ER status was not collected, we used the
administrationof endocrine therapy as a surrogate for ER status. Patientswere
considered to have low clinical risk when the 10-year breast cancer–specific
survival as predicted byAdjuvant! wasmore than 88% for ER-positive tumors
and more than 92% for ER-negative tumors.19 We analyzed the difference
when these patients were considered sentinel node–positive (categorized as
one to three positive lymph nodes) instead of their actual number of involved
nodes (categorized as four to nine, or more than nine positive lymph nodes).
Statistical Analysis
In this study,we tested thehypothesis that theadministrationofadjuvant
systemic therapy was similar in both treatment arms. Among the first 2,000
patients enrolled in the AMAROS trial, 92 patients with a positive sentinel
node were not treated according to their random assignment and were ex-
cluded.All 566 patientswith positive sentinel nodeswhounderwentALNDor
ARTaccording to their randomassignmentwere included in this per protocol
analysis. Theproportions of patients treatedwith adjuvant systemic therapy in
each treatment armwere compared. Associations between the administration
of adjuvant chemotherapy with regard to patient- and tumor-related factors
were evaluated using univariate and multivariate logistic regression analy-
sis. We used Fisher’s exact tests and a forward stepwise selection method
with likelihood ratios to analyze associated variables. All P values were
two-tailed, with a value of .05 or lower considered significant. To investi-
gate whether the treatment arm had any influence on systemic treatment,
interaction terms with all other factors were tested using a cutoff P value of
.10 for significance.
A posteriori, this analysis of 566 patients has approximately 80% power
to detect an odds ratio of 1.65 between the randomized arms (or any other
covariate with two levels). To quantify such an odds ratio further, this trans-
lates to differences in percentages of patients treated with chemotherapy of
55% versus 67% or of 60% versus 71%. This analysis was not preplanned and
therefore there is no a priori expectedmagnitude of differences.
RESULTS
The patient flow is outlined in Figure 1. Of the first 2,000 patients, 41
patients were ineligible because of patient refusal or because they did
notmeet the inclusion criteria. In six of the eligible 1,959 patients, the
SNB procedure was not performed. In 65 patients, the sentinel node
couldnotbe identified.Asa result, the sentinelnode identificationrate
was97%(1,888of1,953). Sixty-fivepercentof thepatients (n1,220)
were sentinel node–negative and underwent no further axillary treat-
ment. Ten patients (0.5%) had only nonaxillary tumor-positive senti-
nel nodes. In these patients, no further axillary treatment was
performed. Thirty-five percent of the patients (n 658)were sentinel
node–positive and were to be treated according to earlier random
assignment betweenALNDandART.Treatment noncompliancewas
14% (n 92). These 92 patients were excluded from further analysis
(Appendix Table A1, online only). In 41 patients, crossover to the
other treatment arm was seen. The crossovers were mainly due to
















Fig 2. Study design. Patients with clini-
cally negative lymph nodes and tumors
less than 3 cm are randomly assigned
between an axillary lymph node dissection
or axillary radiation therapy before the
sentinel node biopsy procedure.
Sub-Analysis of the EORTC 10981-22023 AMAROS Trial
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patient refusalorweredecidedonby local treatingphysicianson thebasis
ofpatientandtumorcharacteristics.Nofurther treatmentwasgivenin15
patients. The majority of these patients had only isolated tumor cells.
Other severe protocol deviations, such as inaccurate lymph node dissec-
tions and treatment delay, were seen in 36 patients. Of the 658 sentinel
node–positive patients, 300 were treated per random assignment with
ALNDand 266 patientswere treatedwithART. These 566 patients form
the study cohort of this report.
Table 1 lists basic patient, tumor, and treatment characteristics.
There were no significant differences between the ALND and ART
arms. The median ages in the ALND and ART arms were 56 and 55
years, respectively. Most patients had a tumor size between 10 and 20
mm (54%, ALND arm; 53%, ART arm) and hadmacrometastases in
their sentinel nodes (61%,ALNDarm; 66%,ART arm). In theALND
arm, 87% of patients had nodal involvement in one to three nodes
(pN1), 8% in four to nine nodes (pN2), and 4% in more than nine
nodes (pN3). Table 2 shows the administration of adjuvant therapy in
both treatment arms.
There was no significant difference in the number of patients
who were treated with adjuvant chemotherapy or hormonal therapy.
In the ALND arm, 58% (n 175) of the patients received adjuvant
chemotherapy and 78% (n 235) received adjuvant endocrine ther-
apy. In theART arm, 61% (n 162) of the patients received adjuvant
chemotherapy and 76% (n 203) received adjuvant endocrine ther-
apy. The overall administration of taxane-based regimens was low,
and there was no clear difference between the two treatment arms
(Appendix Table A2, online only). In the ALND arm, four of the 10
patients who were treated with a taxane-based regimen had at least
four positive lymph nodes. We analyzed the variables affecting the
administration of adjuvant chemotherapy (Table 3). Univariate anal-
ysis showed that age, menopausal status, pathologic T stage, multifo-
cality, the size of sentinel node metastasis, tumor grade, and nodal
involvement (in the ALND arm only) affected the administration of
adjuvant chemotherapy. In multivariate analysis, variables signifi-
cantly affecting the use of adjuvant chemotherapy were age, tumor
grade, the sizeof the sentinel nodemetastasis, andmultifocality (Table
4). Axillary treatment (ALND or radiotherapy), number of positive
sentinel nodes, tumor size, hormonal treatment, radiation to the
breast, and menopausal status were not retained in the model. The
extent of nodal involvement (analyzed as both a continuous and a
categoric variable) did not significantly affect adjuvant chemotherapy
administration in multivariate analysis of the ALND arm separately
(Table 5). When added to this model, the number of positive nodes
has a P value of .47.
To analyze whether clinicians would unjustifiably withhold
chemotherapy in the 37 patients with at least four positive lymph
nodes, we assessed the clinicopathologic risk as predicted by Adju-
vant! as if only the SNB results were known. Adjuvant! classified all
37 patients with four or more positive lymph nodes as clinical high
risk, using the predefined cutoff. When the patients were consid-
ered as sentinel node–positive (categorized as one to three positive
lymph nodes), Adjuvant! classified two patients (5%) as clinical
low risk and 35 patients as clinical high risk. Strikingly, in practice










None 23 8 24 9
Endocrine therapy 95 32 80 30
Chemotherapy 35 12 39 15
Chemotherapy plus endocrine therapy 140 47 123 46
Missing 7 2 0 0
Radiotherapy (breast/chest wall) 257 86 237 89
Axillary radiotherapy 15 5 266 100
Abbreviations: ALND, axillary lymph node dissection; ART, axillary radiation therapy.











Pre 88 29 93 35
Peri 19 6 20 8
Post 176 59 142 53
Unknown 17 6 11 4
pT stage, cm
 1 30 10 33 12
1- 2 162 54 141 53
2- 3 90 30 84 32
3- 5 17 6 7 3
 5 1 0.3 1 0.4
SNB results
Macro 182 61 175 66
Micro 78 26 59 22
ITCs 32 11 31 12
No. of positive sentinel nodes
1 215 72 187 70
2 67 22 62 23
3 14 5 15 6
4 3 1 2 1
13 1 0.3 0 0
pN stage, nodes
1-3 261 87 NA
4-9 25 8 NA
10 12 4 NA
Missing 2 1 NA
Histology
Ductal 216 72 198 74
Lobular 39 13 31 12
Other 45 15 37 14
Grade
I 66 22 64 24
II 141 47 120 45
III 85 28 77 29
Missing 8 3 5 2
Surgery
BCS 263 88 238 89
Mastectomy 37 12 28 11
Abbreviations: ALND, axillary lymph node dissection; ART, axillary radiation
therapy; SNB, sentinel node biopsy; ITC, isolated tumor cell; NA, not applica-
ble; BCS, breast-conserving surgery.
Nine patients had positive nonsentinel nodes (size unknown).
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these two patients were not treated with chemotherapy even
though according to the number of positive lymphnodes theywere
classified as high risk.
DISCUSSION
This study shows no difference in the administration of adjuvant
systemic therapy between the two treatment arms of this trial, which
randomly assigned patients with a tumor-positive sentinel node be-
tween ALND and ART. In an overall multivariate analysis, the treat-
ment arm did not influence the administration of systemic therapy,
and within the ALND treatment arm, the number of involved nodes
was not retained in the multivariate model. Furthermore, we showed
that the proportion of patients having four or more positive lymph
nodes in the ALND arm is low (12%), and that the majority of these
patients (95%) are classified as clinically high risk, even without
knowledge of the actual number of involved lymph nodes. Therefore,
we suggest that theabsenceofknowledge regarding theextentofnodal
involvement in the ART arm does not affect the administration of
adjuvant systemic therapy.
Nonetheless, the extent of nodal involvement is an important prog-
nostic factor that is taken intoaccount in the InternationalUnionAgainst
Cancer (UICC) TNM classification and, therefore, used inmany guide-
lines to select patients for adjuvant treatment.13,17,20,21 The categorization
of patients into groups with one to three (pN1) versus four or more
positive nodes (pN2 and pN3) originated in the early days of adjuvant
chemotherapy forbreast cancer.22Onlypatientswith fourormorenodes
appeared to benefit from adjuvant chemotherapy. Later studies proved
the benefit of chemotherapy in patients with one to three positive nodes
and even subgroups of patientswith tumor-negative nodes.23
Table 3. Variables Affecting the Use of Adjuvant Chemotherapy
Variable
ALND Arm ART Arm
No. of Patients
With CT
Total No. of Patients
in the Group % CT
No. of Patients
With CT
Total No. of Patients
in the Group % CT
No. of patients with CT 175 293 162 266
Age, years
Median 51 in CT group 51 in CT group
64 in non-CT group 63 in non-CT group
Menopausal status
Pre 77 86 90 84 93 90
Peri 13 19 68 15 20 75
Post 72 172 42 55 142 39
pT stage, cm
 1 15 29 52 14 33 42
1- 2 86 158 54 81 141 57
2- 3 63 89 71 61 84 73
3- 5 10 16 63 5 7 71
 5 1 1 100 1 1 100
SNB results
ITCs 10 31 32 10 31 32
Micro 42 77 55 33 59 56
Macro 119 177 67 118 175 67
pN stage
1-3 148 256 58 NA
4-9 7 11 64 NA
 10 19 25 76 NA
Histology
Ductal 126 212 59 122 198 62
Lobular 24 37 65 16 31 52
Other 25 44 57 24 37 65
Grade
I 29 65 45 29 64 45
II 75 137 55 68 120 57
III 66 83 80 64 77 83
Multifocality
Yes 28 33 85 28 33 85
No 147 260 57 134 233 58
Endocrine therapy
Yes 35 58 60 39 63 62
No 140 235 60 80 203 65
Abbreviations: ALND, axillary lymph node dissection; ART, axillary radiation therapy; CT, chemotherapy; SNB, sentinel node biopsy; ITC, isolated tumor cell; NA,
not applicable because the final nodal status remains unknown, although two patients in the ART group had at least pN2 since four tumor-positive sentinel nodes
were removed.
In seven patients, information about the adjuvant treatment is missing.
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At present, hormone responsiveness is the most important dis-
criminator for adjuvant therapy.23 The additional effect of adjuvant
chemotherapy beyond the effect of endocrine therapy reduces with
increasing age. This may lead to the choice for endocrine treatment
alone, without chemotherapy, in older patients with a relatively low a
priori risk. Patientswithmore than four tumor-positive lymphnodes,
indicating a worse prognosis, are more likely to receive additional
chemotherapy.21 According to the current St. Gallen criteria, hor-
mone receptor–positive patients with one to three positive nodes are
at intermediate risk. Patients with four or more positive nodes are at
high risk.
When ALND is omitted in patients with positive sentinel nodes,
the extent of nodal involvement will remain unknown and cannot be
used to select patients for adjuvant systemic therapy. This study shows
that, in clinical practice, nodal extent does not appear to affect the
number of patients receiving adjuvant chemotherapy. Multivariate
analysis shows that the administration of chemotherapy is mainly
based on age, tumor grade,multifocality, and the size of sentinel node
metastasis and not by the nodal extent. This suggests that pN classifi-
cation is only of limited additional importance compared with these
other variables.
Recently, systematic analysis of gene expression patterns using
microarray technology has led to the discovery of prognostic gene
expression signatures, such as the 70-gene profile (MammaPrint) or
the 21-gene profile (OncotypeDX).24,25 These prognostic gene signa-
tures outperformed the current guidelines and are being validated in
two large clinical trials: theEORTCMicroarray inNode-Negative and
1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy
(MINDACT) trial and the Trial Assigning IndividualizedOptions for
Treatment (Rx) (TAILORx) trial.26 In the future, these prognostic
tools may be increasingly used to select patients for adjuvant sys-
temic therapy.
Apart from its use to select patients for adjuvant systemic
therapy, the extent of further nodal involvement is also used to
select patients for postoperative locoregional radiotherapy. The
risk of locoregional recurrences increases with the number of
tumor-positive nodes. Therefore, patients with more than three
positive nodes (pN2 and pN3) have the largest benefit in both
locoregional control and survival. These patients are considered
candidates for postoperative locoregional radiotherapyworldwide,
also following ALND. Considering intermediate-risk patients with
one to three positive nodes (pN1), there is more discussion. The
Danish and Canadian studies27-29 showed that patients with one to
three positive nodes and patients with more than four positive
nodes have a similar absolute survival benefit of 9% after 15 years.
One explanation is that patients with less nodal involvement may
have less systemic disease and therefore a better life expectancy. It is
assumed that, especially in these patients, preservation of locore-
gional control may result in a survival benefit. These studies are
criticized for the relatively high locoregional recurrence rates,
which may be less in similar patient categories nowadays. In sum-
mary, controversy still exists concerning postmastectomy radio-
therapy for pN1 (intermediate-risk) patients.30 Furthermore,
biologic tumor classification and molecular features of a tumor
may better provide discriminators fromwhich patients are likely to
benefit. We hope the Selective Use of Postoperative Radiotherapy
After Mastectomy (SUPREMO) trial (www.supremo-trial.com)
will provide these results.
A few comments on this study are warranted. First, the
expression of hormonal receptors is not collected. We used the
administration of endocrine therapy as a surrogate for endocrine
responsiveness. Since endocrine therapy is recommended only in
estrogen- or progesterone-positive tumors, we assumed that these
data would be comparable.
Second, the overall use of taxane-based regimens in this study
is low. At present, the use of taxanes in early-stage breast cancer
Table 4. Results of Multivariate Analysis Including Variables Affecting the
Administration of Adjuvant Chemotherapy
Covariate
Odds Ratio for
Receiving CT 95% CI P
Age
Per additional year
of age 0.85 0.83 to 0.88  .0001
Grade
I† 1  .0001
II 1.73 0.99 to 3.01
III 7.05 3.56 to 13.96
Size of sentinel node
metastasis
Single ITC† 1 .0001
Clusters of ITCs 1.85 0.27 to 12.49
Micro 4.90 0.80 to 29.98
Macro 9.83 1.65 to 58.79
Multifocality
Yes v no 4.91 2.02 to 11.90 .0004
Abbreviations: CT, chemotherapy; ITC, isolated tumor cell.
In the initial model, the following covariates were attempted: age, grade, size
of sentinel node metastasis, multifocality, pathologic tumor size, menopausal
status, number of positive sentinel nodes, adjuvant hormonal treatment, breast
irradiation, and axillary treatment (axillary lymph node dissection or axillary
radiation therapy). Variables not shown were not retained in the model.
†Reference level.
Table 5. Results of Multivariate Analysis Including Variables Affecting the
Administration of Adjuvant Chemotherapy in the ALND Arm
Covariate
Odds Ratio for
Receiving CT 95% CI P
Age
Per additional year
of age 0.86 0.82 to 0.89  .0001
Grade
I† 1 .0004
II 1.38 0.64 to 2.98
III 5.55 2.21 to 13.95
Size of sentinel node
metastasis
Single ITC† 1 .005
Clusters of ITCs 1.91 0.13 to 28.45
Micro 4.10 0.33 to 51.49
Macro 10.76 0.87 to 133.00
Multifocality
Yes v no 5.53 1.51 to 20.26 .010
Abbreviations: ALND, axillary lymph node dissection; CT, chemotherapy; ITC,
isolated tumor cell.
In the initial model, the following covariates were attempted: age, grade,
size of sentinel node metastasis, number of positive sentinel nodes, nodal
involvement (continuous), multifocality, pathologic tumor size, menopausal
status, adjuvant hormonal treatment, and breast irradiation. Variables not
shown were not retained in the model.
†Reference level.
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has increased and might be influenced by the number of involved
nodes. Similarly, the influence on the administration of trastu-
zumab inHER2-positive patients could not be assessed because the
patients in this studywere treated between 2000 and 2005. Further-
more, systemic treatment recommendations differ between the
United States and Europe.
In conclusion, this analysis shows that in patients with a
tumor-positive sentinel node, treating the axilla with radiation
instead of lymph node dissection, and thus performing an incom-
plete axillary staging, does not appear to significantly influence the
prescription of adjuvant systemic therapy. These results support
the hypothesis that the administration of adjuvant chemotherapy
is mainly based on tumor and patient characteristics and SNB
status and that knowledge of further nodal involvement is redun-
dant. However, these results will be validated in a consecutive
subset of patients accrued to the AMAROS study.
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